Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
about
The retinoid X receptors and their ligandsStructural Basis for Retinoic X Receptor Repression on the TetramerDefining the Communication between Agonist and Coactivator Binding in the Retinoid X Receptor Ligand Binding DomainAdvances in drug design with RXR modulatorsBigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells.Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB.NSC-640358 acts as RXRα ligand to promote TNFα-mediated apoptosis of cancer cellTargeting truncated retinoid X receptor-α by CF31 induces TNF-α-dependent apoptosis.Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potentialBigelovin triggered apoptosis in colorectal cancer in vitro and in vivo via upregulating death receptor 5 and reactive oxidative species.Small compound bigelovin exerts inhibitory effects and triggers proteolysis of E2F1 in multiple myeloma cells.Anti-inflammatory effects of the petasin phyto drug Ze339 are mediated by inhibition of the STAT pathway.Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells.Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential.Overview of the structure-based non-genomic effects of the nuclear receptor RXRα
P2860
Q24562747-5F0EDEBB-353B-4B46-80F2-3CB15FF2E817Q27668012-48E62900-A69D-4216-859B-E647B1A7A60CQ27680515-38BBFEAA-47BD-48A1-9326-407CBA98A853Q28274388-48C3BEC4-51EE-4A4D-9980-56F56ADCE1E6Q35289346-F0C39B6C-1C5E-4ECF-9EE4-91FD7E953E0DQ35612396-E53CC98A-3147-4479-ACB2-0AD9B82853B7Q35956818-2CA82C80-74F9-464A-B707-8266326CE340Q36510879-53A0FEA4-AB8B-43CA-A4C8-6C8F942E6A06Q36758674-CFDE7AE2-AD39-4569-887B-3FBC03A6E320Q37633880-B22C3750-E255-4E30-82D4-BD1EFF2B352EQ39080639-1581386B-7AAB-4F91-ABCD-89F27F0D681BQ40352267-8653C50B-AD6E-4E07-81BE-A90962281E16Q47152429-B28FF205-0FA5-42AF-B778-151B25067684Q47652702-202FBFA6-8E82-4910-82D8-B8DF48FF3A7EQ58798014-5992BC84-CC56-4A7A-B022-3F7797C8E2EC
P2860
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@ast
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@en
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@nl
type
label
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@ast
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@en
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@nl
prefLabel
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@ast
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@en
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@nl
P2093
P1476
Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode
@en
P2093
P356
10.1016/J.JMB.2011.01.032
P407
P50
P577
2011-01-22T00:00:00Z